Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer

• Jun Jiang

  Department of Radiation Oncology, the First People's Hospital of Foshan, Foshan 528000, China

• Wei Hong Wei

  Department of Radiation Oncology, the First People's Hospital of Foshan, Foshan 528000, China

• Tao Xu

  Department of Radiation Oncology, the First People's Hospital of Foshan, Foshan 528000, China

There is no standard treatment for locally advanced cervical cancer, patients with residual tumor after radical concurrent chemoradiotherapy. This study was to investigate the short-term efficacy and safety of the targeted drug apatinib mesylate in patients with tumor residual after radical chemoradiotherapy for locally advanced cervical cancer. Eight patients with residual tumors after localized concurrent chemoradiotherapy with locally advanced cervical cancer were treated with apatinib (250 mg once daily, orally). The short-term efficacy and safety of the eight patients treated with apatinib were initially evaluated. Total Effectiveness (ORR) 37.5% and disease control rate (DCR) 100.0%. The toxicity and side effects were light, mainly manifested as 37.5% of hand-foot syndrome, 37.5% of proteinuria, 25.0% of hypertension, 12.5% of fatigue, 12.5% of rash, and 12.5% of vomiting. No serious toxic side effects associated with the drug were observed. Apatinib mesylate can be safely used in patients with residual tumor after radical chemoradiotherapy for locally advanced cervical cancer. The short-term effect is positive and the side effects are low.

Parkhurst JO, Vulimiri M. Cervical cancer and the global health agenda: insights from multiple policy-analysis frameworks. Glob public Health 2013; 8(10): 1093-108. https://doi.org/10.1080/17441692.2013.850524

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108. https://doi.org/10.3322/caac.21262

Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies [J]. BMC cancer 2010; 10: 529. https://doi.org/10.1186/1471-2407-10-529

Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31(26): 3219-25. https://doi.org/10.1200/JCO.2013.48.8585

Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastro-esophageal junction[J]. J Clin Oncol 2016; (3): 35-38.

Qin SK. Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. [J]. Journal Of Clinical Oncology 2014; 32(15). https://doi.org/10.1200/jco.2014.32.15_suppl.4003

Hu X, Cao J, Hu W, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer [J]. BMC cancer 2014; 14: 820. https://doi.org/10.1186/1471-2407-14-820

Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer [J]. International journal of cancer 2014; 135(8): 1961-9. https://doi.org/10.1002/ijc.28829

Li Z, Kai L, Meizhen S, et al. Randomized, double-blind, placebo-controlled, multicenter phase II clinical trial of apatinib mesylate in advanced non-squamous non-small cell lung cancer [M]. The 15th National Clinical Proceedings of the Oncology Conference and the 2012 CSCO Academic Annual Conference. Beijing 2012; 24.

Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phaseⅡ randomized, open-label trial[J]. J Clin Oncol 2014; 32(15): 17-20. https://doi.org/10.1200/jco.2014.32.15_suppl.4019

Kozloff M, Yood MU, Berlin J, Flynn PJ,Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870. https://doi.org/10.1634/theoncologist.2009-0071

Castelnau-Marchand P, Chargari C, Bouaita R, et al. What to expect from immediate salvage hysterectomy following concomitant chemoradiation and image-guided adaptive brachytherapy in locally advanced cervical cancer[J]. Cancer Radiother 2015; 19(8): 710-7. https://doi.org/10.1016/j.canrad.2015.05.025

Shi D, Liang Z, Zhang C, et al. The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis[J]. BMC Cancer 2018; 18: 308. https://doi.org/10.1186/s12885-018-4232-x

Maohuai C, Hongyu G, Jun X, et al. Short-term efficacy of HIFU combined with systemic chemotherapy in the treatment of 17 cases of cervical cancer after radiotherapy[J]. Shanghai Medical Imaging 2007; 16(4): 303-304.

Kim HS, Kim MK, Kim HJ, et al. Phase ⅡStudy of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer[J]. Epub 2012; 44(2): 97-103. https://doi.org/10.4143/crt.2012.44.2.97

Dueñas-González A, ZarbáJJ, Patel F, et al. Phase Ⅲ,open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage ⅡB to ⅣA carcinoma of the cervix [J]. Epub 2011; 29(13): 1678-85. https://doi.org/10.1200/JCO.2009.25.9663

Mabuchi S, Isohashi F, Okazawa M, et al. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage ⅢB/ⅣA cervical cancer patients[J]. Gynecol Oncol 2017; 28(1): e15. https://doi.org/10.3802/jgo.2017.28.e15

Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth [J]. The Journal of experimental medicine 2012; 209(3): 507-20. https://doi.org/10.1084/jem.20111424

Tian S, Quan H T, Xie C Y, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo [J]. Cancer Sci 2011; 102(7): 1374-80. https://doi.org/10.1111/j.1349-7006.2011.01939.x

Song S, Ewald AJ, Stallcup W, et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival [J]. Nature cell biology 2005; 7(9): 870-9. https://doi.org/10.1038/ncb1288

Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer [J]. Oncogene 2000; 19(49): 5636-42. https://doi.org/10.1038/sj.onc.1203912

Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2002; 20(6): 1692-703. https://doi.org/10.1200/JCO.2002.20.6.1692

Ji G, Hong L, Yang P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report [J]. Onco Targets Ther 2016; 9(3): 643-647. https://doi.org/10.2147/OTT.S96133

• PDF